18616 - Sun Protection Factor Assay
NCT02788162 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2018-12-12
Summary
To evaluate the Sun Protection Factor efficacy on human skin.
Conditions
- Sunscreening Agent
Interventions
- DRUG
-
Coppertone (BAY 987517)
Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation Number - X71-144)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-10-19
- Primary Completion
- 2015-10-21
- Completion
- 2015-10-21
Countries
- United States
Study Locations
More Related Trials
-
Cilostazol 100 mg Tablet Formulations Under Fasting Conditions
NCT00838630 ·Status: COMPLETED ·Phase: PHASE1
-
Capadenoson in Angina Pectoris
NCT00518921 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fasting Conditions
NCT00776113 ·Status: COMPLETED ·Phase: NA
-
Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects
NCT00834873 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body
NCT06393127 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams
NCT00803439 ·Status: COMPLETED
-
Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fed Conditions
NCT00775619 ·Status: COMPLETED ·Phase: NA
-
A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Feeding Conditions
NCT03574285 ·Status: COMPLETED ·Phase: PHASE1
-
The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting Conditions
NCT05218616 ·Status: UNKNOWN ·Phase: PHASE1
-
To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions
NCT00881855 ·Status: COMPLETED ·Phase: PHASE1
-
Meloxicam 15 mg Tablets Under Non-Fasting Conditions
NCT00840879 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.
NCT04111614 ·Status: COMPLETED ·Phase: PHASE1
-
A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions
NCT00864435 ·Status: COMPLETED ·Phase: PHASE1
-
Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects
NCT00834795 ·Status: COMPLETED ·Phase: PHASE1
-
Meloxicam 15 mg Tablets Under Fasting Conditions
NCT00840476 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.
NCT01632449 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition
NCT01577914 ·Status: COMPLETED ·Phase: PHASE1
-
Study Comparing Two Different Tablet Formulations Of Bosutinib Under Fed Conditions
NCT01080365 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of Fenofibrate 160mg Tablets Under Fed Conditions
NCT00775359 ·Status: COMPLETED ·Phase: NA
-
Cefprozil 500 mg Tablets Under Fasting Conditions
NCT00840281 ·Status: COMPLETED ·Phase: PHASE1
-
Food Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg
NCT00650169 ·Status: COMPLETED ·Phase: PHASE1
-
To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions
NCT00881426 ·Status: COMPLETED ·Phase: PHASE1
-
Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.
NCT03168022 ·Status: COMPLETED ·Phase: PHASE1
-
Cefadroxil 500 mg Capsules Under Fasting Conditions
NCT00834275 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Seltorexant in Healthy Participants
NCT04553042 ·Status: COMPLETED ·Phase: PHASE1